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Few large studies have evaluated concordance based on a broad spectrum of human papillomavirus (HPV) types in oral and
genital specimens of mothers and their recently born infants. This information is important in determining whether HPV vaccines
administered prior to pregnancy may be useful for preventing vertical transmission. HPV DNA was positive in 30% of mothers
and 1.5% of newborns. Maternal/newborn concordance (HPV+/+ or HPV−/−) was 71%. Among HPV DNA+ mothers, only 3%
of their infants were DNA+ and only 1 pair had the same HPV type. Among HPV− women, 0.8% of infants were HPV+. HPV
DNA detected in hospitalized newborns reﬂects current infection transmitted to infants during pregnancy or delivery. None of
the mother/baby HPV DNA+ concordance pairs detected viral types found in HPV vaccines suggesting that vaccination prior to
pregnancy is unlikely to be eﬃcacious in preventing vertical transmission.
1.Introduction
Human papillomavirus (HPV) is well recognized for causing
laryngeal papillomatosis, genital warts, and cancer [1, 2].
HPV types are classiﬁed as low-risk, nononcogenic, types,
associated with anogenital warts and laryngeal papillomato-
sis or high-risk, oncogenic, HPV types associated with
cancers of the cervix, anogenital areas, and head and neck
[3]. The most prevalent HPV types associated with genital
and oral cancers are HPV-16, 18, and 33. HPV-6 and
-11 are most commonly associated with neonatal laryngeal
papillomatosis and genital warts.
Although the predominant mode of viral transmission
occurs through sexual contact, HPV also has been found
in virginal women prior to ﬁrst coitus [1, 2, 4]. Studies
suggest that the virus can be transmitted from mother to
infantbeforeorduringchildbirth[5–11].Weandothershave
found that the risk of vertical transmission of HPV DNA
to the oral or genital mucosa of newborns to be rare, 1–5%
[6, 10, 12, 13]. In contrast, other studies suggest the vertical
transmission is common, 40%–80% [7, 12, 14]. Several
studies of persistent HPV DNA, a method for distinguishing
inoculation from true infection, reported maternal/newborn
concordance after birth to be maintained between 37%–83%
at 6 weeks to 6 months after birth [15, 16] whereas another
study has shown a lower 10% prevalence in infants at 24
months of follow-up [14]. Maternal HPV positivity is con-
sistently a risk factor for HPV infection in infants [14–16].
The prevalence of this nonsexual mode of viral transmission
may have an important impact on vaccination strategies and
clinical management of infected women in family planning
before pregnancy. Thus it is important to not only clarify
the frequency of transmission and concordance but also
to determine whether the same HPV types are detected in
mother and infant in an environment controlled for other
potential sources of HPV transmission. The purpose of this2 Infectious Diseases in Obstetrics and Gynecology
study was to assess maternal risk factors for transmission of
HPV to their newborns prior to hospital discharge and to
assess the level of HPV type speciﬁc concordance based on
maternal/infant antibodies and cytologic DNA from genital
and oral specimens.
2. Methods
2.1. Participants. Between 1997 and 2000, all pregnant
women, ages 18 and over, who were being seen in their
third trimester of pregnancy during routine obstetric exam-
inations (n = 582) were recruited into the study at the
University of Iowa Hospitals and Clinics, Department of
Obstetrics/Gynecology. The study included only healthy
women with normal pregnancies. Mothers were excluded if
they were having complicated pregnancies, had a language
barrier, were mentally unable to consent, or were not going
to deliver at the research hospital site and thus would not
be eligible for the aims of the study. All participants signed
an approved Human Subjects Consent form. Not all women
who were recruited could be included in the ﬁnal analyses
because some women delivered elsewhere or the cord blood
was not available at delivery. Among 333 included pregnant
womenwhowereincludedinthestudyanalyses,HPVresults
were evaluated by obtaining cervical and oral cell specimens
and by collecting peripartum serology. Samples from the 333
newborns were obtained from oral and genital areas and
from cord blood to test for HPV status. There were 193
male and 140 female newborns in the study. No same sex
couples or nonbiologic partners were identiﬁed during the
study recruitment.
2.2. Data Collection. After a university-approved human
subject consent form was signed by the mothers, they
completed a self-administered questionnaire of information
about demographics, reproductive, sexual history, and HPV-
related lesions. Newborns were evaluated by the attending
pediatrician for gestational age at birth, gender, type of
delivery, bottle/breast feeding preferences, medical problems
at birth, and number of hours after delivery when the
HPV specimen was obtained from the infant. Maternal
cervical swabs and oral rinses were obtained during the
third trimester of pregnancy and immediately before delivery
by trained obstetricians and nurse practitioners. Maternal
serum samples were obtained aseptically during the delivery
process. Prior to discharge, infants were tested for HPV
DNA by swabbing their genital and oral regions. The
procedures have been described previously [15]. Infant oral
and genital specimens were taken at a median of 42 hours
after birth to reduce the risk of viral inoculation but not
infection of the tissue. The minimum time after birth before
specimens were collected to evaluate HPV DNA was set at
24 hours; however, because two women were planning to be
discharged prior to that time, specimens in their newborns
were collected <24 hours after birth. In males that were
circumcised a portion of tissue was tested for HPV DNA.
Infant serum samples were obtained from the placenta at
birth.
2.3. Laboratory Methods. Serological testing was performed
to determine if an individual had antibodies to HPV-speciﬁc
capsid proteins (virus-like particles/VLPs). The procedures
have been described elsewhere [17–21] .T h ep r e s e n c eo f
antibodies to antigens derived from HPV-speciﬁc proteins
was determined using an ELISA test using HPV types 16,
18, 31, and 33 VLPs as antigens [22] and these were deﬁned
as HPV high-risk types (HPV-HR). HPV 6 and 11 VLPs,
deﬁned as low-risk types (HPV-LR) were not available at
the time these analyses were tested. Background reactivity
was determined in wells without antigen. Their absorbances
were subtracted from corresponding values obtained in the
presence of antigen. Control sera known to be positive
and negative were tested on each plate. For the cutoﬀ
level calculation, above which optical density values were
considered positive, 10 standard sera from regular blood
donors known to be HPV-antibody negative were included
on each plate. The means and SD were calculated for each
antigen separately, the cutoﬀ point was represented as the
mean absorbance of the control specimen plus 3 SD.
Sample preparation, PCR analyses, DNA hybridization,
and HPV typing procedures for assessment of exfoliated
oral cells were based on a standard protocol described
previously [23, 24]. Each PCR reaction included primers to
amplify the β-globin gene [25] to verify adequate DNA and
adequacy of the PCR ampliﬁcations of the cellular DNA.
All oral cell specimens tested positive for the β-globin gene.
Two percent of the DNA (typically 50–200ng) extracted
from cell specimens was PCR-ampliﬁed with MY09 and
MY11 primers [26] to detect HPV and a primer (HMB01)
designed to amplify HPV-51 to improve detection of this
type [27]. The PCR product ﬁrst was examined for the
presence of a 400nt HPV ampliﬁed band on ethidium
bromide stained 1% agarose gels. An aliquot of the PCR
product of all those specimens that were HPV-negative
after staining was hybridized by the dot blot method with
32P-labeled probes for a more sensitive detection of HPV
DNA. Those samples positive only after the membrane
hybridization underwent hemi-nested PCR-ampliﬁcation
with MY09 and GP5+ primers [28]. DNA sequencing was
used to determine the HPV types in each HPV-positive spec-
imen, performed by dye-termination on a DNA sequencer
(Applied Biosystems-PE). The nucleotide sequences were
compared to GenBank sequences using the BLAST program
[29].
2.4. Statistical Analysis. Logistic regression was used to esti-
mate odds ratios (ORs) and 95% conﬁdence intervals (CIs)
for HPV seropositivity associated with mother and newborn
characteristics adjusting for number of sexual partners and
maternal history of an HPV-related disease. Concordance
was examined using McNemar’s test for matched pairs in
2 by 2 tables utilizing mother and newborn VLP and HPV
DNA results. The Kappa statistic was used to measure
agreement in HPV positivity status between mother and
newborn sera samples. Statistical signiﬁcance was noted
at .05 and all tests were 2-sided. All analyses were performed
using the SAS statistical package [30].Infectious Diseases in Obstetrics and Gynecology 3
Table 1: Demographic characteristics and risk factors for HPV DNA positivity among mothers (n = 333).
Characteristic N (% HPV+)
1,2 Adjusted OR
95% CI
3
Age
≤24 39/81 (48.1) 4.2 (2.2–7.8)
25–29 42/110 (29.1) 2.1 (1.1–3.8)
≥30 28/142 (19.7) reference —
Race
White 83/281 (29.5) reference —
Other 16/52 (30.8) 1.2 (0.6–2.4)
Education
≤12 37/78 (47.4) 3.4 (1.8–6.7)
13–16 39/142 (27.5) 1.3 (0.7–2.5)
≥17 23/113 (20.4) reference —
Age ﬁrst intercourse
<20 88/258 (34.1) 1.9 (0.9–4.1)
≥20 11/75 (14.7) reference —
Number of partners
1-2 15/105 (14.3) reference —
≥3 83/225 (36.9) 3.1 (1.7–5.8)
Parity
1-2 56/193 (29.0) reference —
≥3 43/140 (30.7) 1.0 (0.6–1.6)
OC Use
Never 16/44 (36.4) reference —
Ever 83/289 (28.7) 0.5 (0.2–1.02)
Smoking
Never 51/220 (23.2) reference —
Ever 48/113 (42.5) 1.8 (1.04–3.0)
Alcohol
Never 66/210 (31.4) reference —
Ever 33/123 (26.8) 0.6 (0.3–0.96)
HPV-related disease
Never 62/244 (25.4) reference —
Genital warts 15/39 (38.5) 1.4 (0.7–2.8)
Cervical dysplasia 30/71 (42.3) 1.8 (0.98–3.1)
Cervical cancer 4/5 (80.0) 8.0 (0.9–73.4)
Pap smear
WNL 57/219 (26.0) reference —
ASCUS 12/42 (28.6) 0.8 (0.4–1.8)
L-SIL 30/71 (42.3) 1.1 (0.4–3.3)
HPV VLP
HPV– 57/225 (25.3) reference —
HPV+4 42/108 (38.9) 1.3 (0.8–2.2)
1HPV DNA types include HPV-6, 11, 16, 18, 31, 33, 39, 51, 53, 54, 56, 58, 59, 61, 66, 69, 70, 83, 84, other/unnamed types; 2Based on HPV+ in cervical/genital
and/or oral samples; 3adjusted for number of sexual partners and history of an HPV-related disease; 4HPV-HR VLP types HPV-16, 18, 31, 33.
3. Results
Table 1 shows the demographic characteristics and risk
factors for HPV DNA in 333 healthy pregnant women
positive for one or more HPV types detected in the cervix
and/or oral mucosa. The mean age at delivery was 29 (range:
18–44 years), 16% were nonwhite/nonHispanic races, and
77% had greater than high school education. More than
three quarters had sexual intercourse before the age of
21, two-thirds had 3 or more partners before the current
pregnancy, over half had two or fewer prior pregnancies, and
most had used oral contraceptives. Over 25% of the women4 Infectious Diseases in Obstetrics and Gynecology
Table 2: HPV types and frequencies in mothers and newborns (N = 333).
Mother Newborn
DNA Serum3 DNA Serum3
Cervical Oral5 Cervical/Oral Genital Oral Genital/Oral
HPV status N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
HPV+
1 93 (27.9) 10 (3.0) 99 (29.7) 108 (32.4) 2 (0.6) 3 (0.9) 5 (1.5) 103 (30.9)
HPV-LR
1,2 27 (8.1) 3 (0.9) 26 (7.8) 2 (0.6) 1 (0.3) 3 (0.9) 0 (0.0)
6 3 (0.9) 1 (0.3) 4 (1.2) 0 (0.0) 0 (0.0)
11 2 (0.6) 2 (0.6) 0 (0.0) 0 (0.0)
HPV-HR
1,2 66 (19.8) 7 (2.1) 73 (21.9) 108 (32.4) 2 (0.6) 2 (0.6) 103 (30.9)
16 22 (6.6) 2 (0.6) 24 (7.2) 47 (14.1) 1 (0.3) 49 (14.7)
18 8 (2.4) 8 (2.4) 46 (13.8) 45 (13.5)
31 19 (5.7) 2 (0.6) 21 (6.3) 41 (12.3) 39 (11.7)
33 2 (0.6) 1 (0.3) 3 (0.9) 40 (12.0)
4 36 (10.8)
4
HPV-6,11,16,18 35 (10.5) 2 (0.6) 37 (11.1) 0 (0.0) 1 (0.3) 1 (0.3)
1Percentages based on number of cases; 2HPV-HR = high risk types detected (HPV-16, 18, 31, 33, 39, 51, 56, 58, 59, 66, 70); HPV-LR = low risk types
detected (HPV-6, 11, 53, 54, 61, 69, 83, 84, other/unnamed types); the number of HR and LR types do not sum to total number of HPV+ in cervical group
because results represent the 2 cervical samples combined; and individuals may have multiple types, including both HR and LR types; 3number of HR types
do not sum to total number of HPV+ because of multiple infections; 4data not available, some VLP types not tested.
had a history of an HPV-related lesion and ﬁve had had
histologically-conﬁrmed cervical cancer. The majority of
newborns were males (58%), ≥39 weeks gestation (67%),
and born by vaginal delivery (89%).
Risk factors included in Table 1 are based on HPV DNA
since it is indicative of current infection as opposed to HPV
VLPs which represent both past and current infection. After
adjustment for number of partners and history of an HPV-
related disease in mothers, younger age, lower education,
greater number of partners, smoking, cervical dysplasia,
and cervical cancer were associated with an increased risk
of maternal HPV DNA. Newborn HPV DNA positivity
was not associated with gender, feeding method, type of
delivery, or gestational age (data not shown). Among the
333 women, there were 295 (87%) vaginal deliveries and 38
(13%) C-sections. Among the 99 DNA positive mothers, the
proportion of vaginal (n = 86) and C-section (n = 13)
deliveries were also 87% and 13%, respectively. For HPV
DNA transmission, only 3 (1%) of the 86 vaginal deliveries
wereconcordantandnoneofthe13DNApositiveC-sections
(P-value >. 99). For serologic transmission, 35% (30/86) of
the vaginal deliveries and 38% (5/13) of the C-sections were
concordant. After adjusting for a history of HPV disease, the
OR comparing vaginal to C-section deliveries was 1.1 (0.1–
23.1) for DNA transmission and 0.9 (0.3–3.0) for serologic
transmission. There were no signiﬁcant associations between
seropositivity to anti-HPV VLPs (HPV-16, 18, 31, 33) in
mothers and risk of HPV-HR DNA for these same four HPV
types (data not shown).
HPV frequency and types in mothers and newborns
are shown in Table 2. HPV DNA, which tests for a current
infection, showed thatamong mothers, 30% were HPV DNA
positive: 28% in the cervix and 3% in the oral mucosa;
and 22% of mothers had an HPV-HR type. Multiple types
were detected in 13.5% (n = 45), only in the cervix. The
two most common HPV-HR types in mothers were HPV-16
(33%) and HPV-31 (29%) and these types were more
frequent in both cervical and oral mucosa. Less common
HPV-HR DNA types included 18, 33, 39, 51, 56, 58, 59,
66, and 70. The overall prevalence of HPV-16, 18, 31, and
33 DNA was 16% in mothers. The overall prevalence of
HPV-LR DNA in mothers was 8% and the most common
LR types were HPV-53 (19%), HPV-61 (14%), and HPV-
83 (14%); other less frequently detected types were HPV-
6, 11, 54, 69, 84, and several unnamed types. The table
also shows the frequency of HPV-6, 11, 16, 18 types which
are found in current HPV vaccines. Maternal and newborn
data indicated that only about one-third of their HPV+
DNA infections included these four vaccine types. The
prevalence of HPV DNA in newborns was 1.5% (Table 2)
and there was no signiﬁcant diﬀerence in sample collection
time between the HPV+ and HPV− newborns: 40hrs.
versus 41.5hrs (P>. 10). Three newborns were detected
with HPV DNA in oral samples: 2 HPV-HR types (HPV-
16 and 51) and 1 HPV-LR type (HPV-61). Two newborn
HPV-LR vulvar samples also were positive for HPV-61
whereasnoneofthecircumcisiontissuesampleswaspositive.
No multiple infections were found in the HPV DNA of
newborns.
The seropositivity rate to VLPs 16, 18, 31, and 33 was
32% in mothers and 31% in newborns. The prevalence
was similar in mother and infant for each VLP type
tested (Table 2). Among the seropositive mothers, 58% were
detected with a single infection and 42% with multiple
infections. In infants, 44% were seropositive for multiple
types. In mothers, 13% were HPV DNA+/VLP+, 17%
were DNA+/VLP−, 20% were DNA−/VLP+, and 50%
were DNA−/VLP−. In the DNA+/VLP+ mothers, the type-
speciﬁc concordance ranged from 25%–50%, thus a high
percentage (50–74%) of DNA+ for HPV-16, 18, 31, or 33
were type-speciﬁc seronegative. None of the infant DNA+
types matched their anti-VLP antibody types.Infectious Diseases in Obstetrics and Gynecology 5
Table 3: Concordance between mother and newborn for anti-HPV
VLP 16, 18, 31, or 33 (N = 333).
Mother Newborn
Antibodies VLP + VLP –
N (%) N (%)
VLP + 94 (28.2) 14 (4.2)
VLP − 9 (2.7) 216 (64.9)
The mean HPV specimen collection interval between
enrollment at the third trimester and delivery was 71.4 days.
There was no signiﬁcant association between the interval
between the third trimester and delivery specimen collection
period and subsequent risk of HPV transmission. Based
on serology, the mean intervals between HPV seronegative
versus HPV seropositive transmission was 74 days and 60
days, respectively, (adjusted P-value = .20). Based on DNA
transmission, the mean intervals for HPV DNA-negative
versus HPV DNA-positive transmission was 63 days and 49
days, respectively (adjusted P-value = .59). The overall mean
interval time (based on both serology and DNA) was not
signiﬁcantly related to the transmission rate.
Next we examined concordance between maternal and
newborn samples for anti-HPV VLPs (Table 3). There was a
high concordance (93%) and low discordance rate between
maternal and newborn antibodies (P = .30) and high
agreementinHPVseropositivity(K = 0.84,0.78–0.90).Type
speciﬁc concordance rates were between 96%–97%.
The HPV DNA+ concordance rate between mothers and
newborns was 71% (P<. 0001), mostly due to HPV–
ﬁndings in both groups (Table 4). If the mother was HPV+,
the risk in the infant was increased (OR=3.6, CI: 0.6–22.0)
but the low number of positive newborns resulted in the
wide CIs. Among the 30% HPV+ mothers, 3% (n = 3)
of their infants were HPV+ compared to 0.8% (n = 2)
of infants in HPV– mothers. Although there were three
mother/baby pairs that were both HPV+, HPV type-speciﬁc
concordance occurred in only one case, for HPV-51 in the
maternal cervix and oral mucosa of the newborn. The other
two HPV+ mother/baby pairs were HPV-39/HPV-61 and
HPV-99/HPV-61. ThetwoHPV+infantswithHPV-mothers
were detected with HPV-16 and HPV-61. Only one of the
ﬁve DNA+ newborns had a type contained in current HPV
vaccines (HPV-16). Thus the ﬁndings were substantially
diﬀerent from those of serology which were essentially those
of the mother whereas the DNA ﬁndings represented current
infection in both mother and infant.
4. Discussion
This large epidemiologic study evaluated HPV concordance
between mothers and newborns by examining viral fre-
quency and types both in serum and in cytology and
identiﬁed risk factors for vertical transmission. Previous
studies [6, 7, 14], including ours [10, 11], have evaluated
HPV vertical transmission by examining the prevalence of
HPV DNA positivity in mothers and newborns, and less
Table 4: Concordance between mother and newborn for HPV
DNA1 (N = 333).
Mother Newborn
DNA
1 HPV + HPV –
N (%) N (%)
HPV + 3 (0.9) 96 (28.8)
HPV − 2 (0.6) 232 (69.7)
1HPV+ cervical/genital and/or oral for any HPV type.
often, in investigations with suﬃcient DNA of oral/genital
specimens [6, 13, 15, 16] have determined HPV types and
type-speciﬁc concordance between mother and newborn.
In past studies, we found that the maternal prevalence
rate of HPV DNA from oral/genital specimens was 31%
whereas it was <2% in her infant [10, 11] rates similar
in this investigation based on a diﬀerent study population.
Although the seropositivity rates for HPV-16, 18, 31, 33 in
thisanalysisweresimilartothematernalDNA+ratesoverall,
31–32%, only half of the HPV DNA+ mothers were detected
with these same four HPV serologic high-risk types; and the
singleHPV-16DNA+infantwasHPVseronegative.Relevant
to this ﬁnding is the fact that there was no association
between type of delivery and rate of vertical transmission;
thus vaginal delivery does not appear to convey a greater
risk of HPV from mother to newborn even where there was
concordance in HPV type.
Analyses of HPV serologic concordance in mothers and
newborns have not been performed previously primarily
because mothers provide immunologic antibodies for their
newborns in the ﬁrst 3–6 months of life and there is likely
to be little discordance in HPV status or types between
mother and newborn. This was indeed the outcome with
few exceptions, most likely due to either maternal viral
clearance when she tested seronegative and her newborn
tested seropositive or when infants had not yet mounted a
suﬃcient antibody level from mothers who recently acquired
an HPV infection and tested seropositive. Thus, this is the
ﬁrst study to have validated fetal acquisition of maternal IgG.
Since a comparison of maternal anti-HPV serologic
ﬁndings does not provide a valid measure of transmission
of infection to infants, the clinical focus is limited to concor-
danceinDNAtypesfromexfoliatedcells.ThissourceofHPV
detection has the advantage of measuring current infection
in the individual unlike serologic markers. Supported by our
former[10,11]andcurrentinvestigation,andthoseofothers
with large (N>150) maternal/newborn samples [6, 13],
vertical transmission of HPV DNA detected in genital and
oral cells is uncommon, <5%. Despite that low prevalence,
we found that the risk of vertical infection was increased
if the mother was detected with HPV prior to delivery or
had an HPV-related lesion prior to delivery (OR = 3.0, 1.8–
4.0). Mothers with a history of an HPV-related disease had
a transmission rate of 47% versus 23% in women without
ah i s t o r y( P<. 0001). Yet only one of the ﬁve HPV+
newborns was detected with an HPV vaccine type (HPV-16).
Furthermore, in this study the genitals in newborns were as
likely to be infected as the oral mucosa; thus concern that6 Infectious Diseases in Obstetrics and Gynecology
vertical transmission of HPV will primarily aﬀect the oral
mucosa (and thus the potential for laryngeal papillomatosis)
does not attend to the larger concern about transmission
to genital mucosa areas. The risk of genital dysplasia and
cancer in adolescents and young adults based on vertical
transmission may be important, as it is for HPV-related oral
papillomatosis.
Although others suggest that the frequency of vertical
transmission is much higher [14–16], these ﬁndings are
most likely due to small sample sizes that produce unstable
frequency rates, and inoculation rather than infection from
specimens taken immediately after birth especially those
from nasopharyngeal aspirates, or PCR contamination. We
prepared and maintained collected specimens, and per-
formed PCR preparation in a separate building from that
where the PCR assay was conducted to reduce contamina-
tion. In addition, we examined the most commonly detected
HPV types by sequencing and veriﬁed that there was not a
high frequency of any one variant and that the variant in
mother/baby was the same.
W ea r ea m o n go n eo ft h ef e wt oh a v ee x a m i n e dH P V
DNA type-speciﬁc maternal/newborn concordance in a
large patient population [10–13] .A m o n gm o t h e r / b a b yp a i r s
infected with HPV, we found low type-speciﬁc concordance,
17%(1/6),inastudyof574mother/babypairsand20%(n =
1/5) in this analysis, both studies using DNA sequencing
to identify a wide variety of types. In contrast, Tseng
et al [12], detected 100% of HPV-16/18 concordance in
oral/genital specimens of 301 mother/baby pairs (27/27) as
didTenti[13](11/11:4HPV-16/18,7otherunspeciﬁedtypes
matched), but the latter study ﬁnding was based on newborn
nasopharyngeal aspirates taken at birth and likely reﬂects
maternal contamination to the newborn. These two studies
limited assessment to HPV-16 and -18 which accounted for
onlyhalfoftheHPVDNAtypesdetected.Thusthefrequency
of vertical transmission in type-speciﬁc concordance needs
further investigation.
It was surprising that the most common HPV DNA
types that have been reported in the oral mucosa, HPV-16,
18, 31, and 33, and which are among the most frequent
identiﬁed in the cervix [31], did not have type-speciﬁc
concordance to VLP types in the same individual, mother
or newborn. We found that 20% of DNA negative mothers
wereVLPseropositiveforoneofthefourHPVtypes.Possible
reasons for this discordant ﬁnding may be due to inadequate
HPV copy number to detect infection (latent infection),
clearance of infection prior treatment of an HPV-lesion
which may have eliminated the lesion with the infection,
or lack of an immune response. A number of large studies
of HPV infection in healthy young women have found
comparable DNA [32–34] and VLP seroprevalence rates in
young women to those in our low-risk pregnant group
[35, 36]. Interestingly, there was a high proportion of women
(17%) who were DNA positive to HPV-16, 18, 31, or 33 but
whodidnothaveanti-VLPantibodiestothosespeciﬁctypes.
These infections may be associated with the inability of the
individual to mount an antibody response, inadequate time
for a recent infection to produce an immune response, or
low level viral replication that does not produce a detectable
antibodyresponse,aﬁndingreportedbyNonnenmacherand
Schiller as well [36].
Among the strengths of this study was the ability to
evaluate type-speciﬁc concordance of DNA and serologic
HPV results between mothers and newborns. In comparison
with other studies which tested for less than six HPV DNA
types, our study sequenced HPV DNA and thus tested
for all types. The conclusion remains, however, that DNA
concordance and thus vertical transmission is low between
mother/newborn oral and genital sites. The large sample
size in this study allowed investigating the concordance of
HPV positivity in mothers and their newborns. The size also
allowed not only an assessment of stable prevalence rates but
also examination of maternal risk factors for HPV infection
in the newborn as a potential method for identifying infants
at high-risk of acquiring this viral infection. Based on the
low HPV DNA positive maternal/neonate concordance, this
suggests that prophylactic HPV vaccination during family
planning prior to pregnancy is unlikely to be eﬃcacious
in preventing vertical transmission. More importantly, the
ﬁndings suggest that because vertical transmission of HPV
is low, the suggestion that women be vaccinated prior to
pregnancy is unlikely to be eﬃcacious.
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